CME
Preventing Disease Recurrence with Adjuvant Therapy in Stage IIB/IIC Melanoma
June 09, 2023
Host: Jason J. Luke, MD, FACP Guest: Tara Mitchell, MD The 5-year recurrence rates for stage IIB and IIC melanoma are up to 46%, but now new immunotherapy options are FDA-approved for the adjuvant treatment of stage IIB and IIC melanoma. Fin
Visit Podcast Website
RSS Podcast Feed
Subscribe
Share
Add to MyCast
Gain access to Blubrry tools that help build your podcast, including free podcast stats!